News | Stents | October 26, 2015

Medinol Completes Enrollment In BIONICS Trial of eDES Coronary Stent System

International trial will compare efficacy of Medinol’s elastomeric drug-eluting stent to Medtronic’s Resolute Integrity stent system

Medinol, BIONICS Trial, completes enrollment, eDES coronary stent system, elastomeric drug eluting stent

The eDES elastomer coating before and after expansion. Image courtesy of Medinol Inc.

October 26, 2015 — Medinol announced in September the completion of enrollment in its BIONICS trial to evaluate the safety and effectiveness of a new coronary stent system, the first-ever elastomeric drug eluting stent (eDES).

The BIONICS trial is a global, prospective, randomized, multicenter, clinical trial enrolling 1,918 patients in the United States, European Union, Canada and Israel. The results will be submitted to the U.S. Food and Drug Administration (FDA) for the U.S. approval of the eDES for the treatment of patients with narrowing or blockage of their coronary arteries.

The device is coated with an elastomer that maintains a smooth and uniform stent surface designed to prevent the cracking or peeling that may occur with brittle polymers used in other DES during the stent crimping and deployment processes. The stent is comprised of cobalt chromium and manufactured and coated in flat panels utilizing Medinol's patented QualitySurface technology and contains a "limus" family drug, intended to prevent restenosis. The eDES design is based on the clinically proven NIRxcell stent architecture intended to enhance conformability, scaffolding and radial strength. The delivery system features a distinctive spring tip that is simultaneously more pushable and flexible than the plastic tips used on other delivery systems. 

"The design of eDES enhances stent deliverability and conformability for the treatment of complex coronary disease. The system is unique from other products currently being offered, and will be a great addition to our current treatment options." said David Kandzari, M.D., FACC, director of interventional cardiology at Piedmont Heart Institute, Atlanta, and principal investigator for the BIONICS trial.

Additionally, Kandzari was impressed with several aspects of the study. "One of the distinctive aspects of the study is how inclusive the enrollment criteria is, allowing for almost all patient populations to be included in the study, and making it very relevant to the populations we see in our practices today. We look forward to getting the results after follow-up," he said.

The BIONICS clinical trial is a 1:1 randomized study comparing the eDES System to Medtronic's Resolute Integrity Stent System. The primary endpoint of the study is target lesion failure (TLF) as determined at 12 months. The eDES System is an investigational device and is not available for commercial sale.

For more information:

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Overlay Init